Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.49 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18103704 | 1.00 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL3418556 | 1.00 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL7383848 | 1.00 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7873502 | 0.98 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7876596 | 0.98 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL25365192 | 0.98 | CYP1A2 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL29035113 | 0.98 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7876588 | 0.98 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL2238814 | 0.98 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL197230 | 0.98 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969770-B2 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9849112-B2 | Pyrrole compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-12-26 | — | — | US | disclosed |
| US-20170015705-A1 | PYRROLE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458193-B1 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9458138-B1 | Pyrrole compounds as granzyme B inhibitors | viDATherapeutics Inc. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-20120142939-A1 | PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF | DIPHARMA FRANCIS S.R.L. (IT) | 2012-06-07 | — | — | US | disclosed |
| EP-2460808-A1 | Process for the preparation of fosinopril and intermediates thereof | Dipharma Francis S.r.l. (IT) | 2012-06-06 | — | — | EP | disclosed |
| EP-2264039-A1 | Process for the preparation of fosinopril and intermediates thereof | Dipharma Francis S.r.l. (IT) | 2010-12-22 | — | — | EP | disclosed |
| US-20100297711-A1 | PROCESS FOR THE SYNTHESIS OF FOSINOPRIL AND INTERMEDIATES THEREOF | DIPHARMA FRANCIS S.R.L. (IT) | 2010-11-25 | — | — | US | disclosed |
| CN-101486672-A | Method for synthesizing trans-4-cyclohexyl-L-proline hydrochloride | JIANGDU XIHUA CHEMICAL CO LTD (CN) | 2009-07-22 | — | — | CN | disclosed |
| CN-101486672-A | Method for synthesizing trans-4-cyclohexyl-L-proline hydrochloride | JIANGDU XIHUA CHEMICAL CO LTD (CN) | 2009-07-22 | — | — | CN | disclosed |
| US-4851514-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, REACTING CERIUM TRICHLORIDE WITH PHENYLLITHIUM TO PRODUCE TRIPHENYL CERIUM | E. R. SQUIBB & SONS, INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4734508-A | GRIGNARD REACTION WITH TRIPHENYLCERIUM | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142939-A1 | PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF | FOS, FOSB, NPPA | DPP4 281/4885GRIN2D 2109/4885GRIN3B 1364/4885 |
| US-20170015705-A1 | PYRROLE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, CTSB, DNASE1L3 | DPP4 1058/4885GRIN2D 3377/4885GRIN3B 1023/4885 |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, CTSB, RNPEP | DPP4 319/4885GRIN2D 3294/4885GRIN3B 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.